Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
ALT
Altimmune
$3.61
Chart
$5.8 (-37.76%)
$5.59 (-35.42%)
$5.59 (-35.42%)
$6.62 (-45.47%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
ALT
Altimmune
Current Price
$3.61
Login to view Altimmune (ALT) recommendation from the last 90 days from financial news and social media.
Chart
$5.8 (-37.76%)
$5.59 (-35.42%)
$5.59 (-35.42%)
$6.62 (-45.47%)
ALT Latest Analysis
Altimmune: Deciphering The MASH Crash (Rating Upgrade).
Thu Jun 26, 2025
Madrigal Viking among notable gainers after Altimmunes MASH setback.
Thu Jun 26, 2025
INVESTOR ALERT: Investigation of Altimmune Inc. (ALT) Announced by Holzer & Holzer LLC. ) complied with federal securities laws. On June 26 2025 Altimmune announced topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) revealing that the trial did not demonstrate statistical significance for the endpoint of improving fibrosis while not worsening MASH. Following this news the price of the Company'.s stock ...
Thu Jun 26, 2025
Altimmune plunges after mid-stage trial data for MASH therapy.
Thu Jun 26, 2025
Altimmune Bit Digital Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursdays Pre-Market Session. United States stock futures were higher this morning with the Dow futures gaining around 100 points on Thursday.Shares of ) fell sharply in today'.s pre-market trading after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide in the treatment of MASH.Altimmune shares dipped 61.2% to $2.99 in the pre-market trading session.Here are some o
Thu Jun 26, 2025
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH. First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks
Thu Jun 26, 2025
Altimmune stock falls after MASH treatment trial results.
Thu Jun 26, 2025
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Associations Scientific Sessions. (Nasdaq: ALT) a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Associations (ADA) 85th Scientific Sessions to be held in Chicago IL from June 20-23 2025. Pemvidutide is a novel investigational GLP-1/glu
Fri Jun 13, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
